Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.2.
| Autor: | Owen DH; Ohio State University, Columbus OH., Singh N; Postgraduate Institute of Medical Education and Research, Chandigarh, India., Ismaila N; American Society of Clinical Oncology, Alexandria, VA., Masters G; Helen F. Graham Cancer Center and Research Institute, Newark, DE., Riely GJ; Memorial Sloan Kettering Cancer Center, New York, NY., Robinson AG; Kingston General Hospital, Queen's University, Ontario, Canada., Schneider BJ; University of Michigan Health System, Ann Arbor, MI., Jaiyesimi IA; Corewell Health William Beaumont University Hospital Royal Oak and Oakland University William Beaumont School of Medicine, Rochester, MI. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Aug 20; Vol. 41 (24), pp. e63-e72. Date of Electronic Publication: 2023 Jul 11. |
| DOI: | 10.1200/JCO.23.01055 |
| Abstrakt: | Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis; as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix 1 and Appendix 2). Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline . |
| Databáze: | MEDLINE |
| Externí odkaz: |
|